Lymphedema Tarda After Liver Transplantation: A Case Report and Review of the Literature
Sammy Saab,1 Stephen Nguyen,2 James Collins,3 Gregg Kunder,4 Ronald W Busuttil5

We present a patient with lymphedema that developed after orthotopic liver transplantation. The cause of the posttransplant lymphedema was likely related to a developmental abnormality of the lymphatic system that was exaggerated by refractory chylous ascites. A peritoneal fluid with a milky appearance, chylous ascites is rich in triglyceride and is caused by the obstruction or disruption of abdominal lymphatic channels. It is a rare complication that may develop after trauma or abdominal surgery or as a result of a malignant disease [1], and it is even more uncommon after liver transplantation [2]. Therapy for chylous ascites involves treating its underlying cause. In the patient we describe, lymphedema tarda, which was diagnosed 6 months after liver transplantation, was likely caused by chylous ascites and a developmental abnormality of the lymphatic system.

Key words: Chylous ascites, Lymphedema tarda, Evaluation, Liver transplantation

Case Report

In June 2004, a 49-year-old man underwent orthotopic liver transplantation (OLT) without venovenous bypass for decompensated liver disease caused by hepatitis C and alcohol abuse. The manifestations of his liver disease included hepatic encephalopathy, refractory ascites, extreme fatigue, lower-extremity edema, and hepatocellular carcinoma. The ascitic fluid was clear and the color of straw. The serum ascites gradient was greater than 1.1 g/dL. After surgery, this patient was discharged with instructions to continue treatment with mycophenolate mofetil, prednisone, tacrolimus, trimethoprim/sulfamethoxazole, and ganciclovir. At discharge, his aspartate amino transferase (AST) and amino alanine transferase (ALT) values were 39 U/L and 78 U/L, respectively.

One month after the transplantation, the patient underwent a liver biopsy to determine the cause of newly elevated values of AST (284 U/L) and ALT (596 U/L). The results of a percutaneous liver biopsy were consistent with recurrent mildly active chronic hepatitis C and portal fibrosis. Two months after his surgery, straw-colored ascites developed, and the following results of liver testing revealed worsening hepatic function: serum total bilirubin, 9.0 mg/dL; serum creatinine, 1.8 mg/dL; alkaline phosphatase, 286 U/L; ALT, 397 U/L; and AST, 508 U/L. The hepatitis C viral load at that time was 2,840,000 IU/mL. A 10-cm 10-Fr biliary stent was placed during endoscopic retrograde cholangiopancreatography in the common bile duct to ensure a smooth anastomotic stricture. A repeat liver biopsy revealed chronic hepatitis C with mild lymphocytic infiltrates and periportal fibrosis. Treatment with pegylated interferon and ribavirin for recurrent hepatitis C was initiated.

In March 2005, 9 months after the transplantation, bilateral nonpitting lower-extremity edema and diuretic-refractory ascites developed and were treated with large-volume paracentesis every 2 weeks (± 0.66 week). During each paracentesis treatment, a mean (± SD) volume of 9 L (± 2.5 L) was removed. The ascitic fluid was milky, and the patient’s triglyceride value was 173 mg/dL (± 46.2 mg/dL). The ascitic fluid albumin value was < 1 g/dL, and the mean serum albumin value was 2 g/dL (± 0.22 g/dL). The mean serum creatinine value was 1.7 mg/dL (± 0.2 mg/dL), and the serum triglyceride value ranged from 248 to 255 mg/dL. The results of bacterial and fungal cultures and cytologic studies were consistently negative. Magnetic resonance imaging (MRI), including MRI angiography and venography of the abdomen and pelvis, revealed marked ascites and patent blood vessels. The results of the hepatic venogram and pressure measurements showed no peritoneal abnormality, portal hypertension, or hepatic vein thrombosis. The results of a transjugular liver biopsy indicated mild lymphocytic infiltration and periportal fibrosis.

Because of the patient’s persistent chylous ascites, a lymphangiogram was performed to determine whether the thoracic duct was intact. The diagnosis of lymphedema tarda (Meige disease) was based on the results of the bipedal lymphangiogram, which demonstrated insufficient lymphatic drainage from the left lower extremity and lymph nodes within the femoral triangle as well as mild fibrosis over the dorsal fascial planes (Figures 1, A and B; and 2, A and B) [3]. Fluoroscopically guided cannulation of a single lymphatic vessel over the dorsum of the right foot revealed impedance to the flow of ethiodized oil (Ethiodol) contrast medium. Fluoroscopically guided cannulation of the lymphatic vessel over the left foot showed the flow of Ethiodol into a single dilated lymphatic vessel (as opposed to the usual 6 to 10 such vessels) over the medial left thigh and into a single superficial inguinal lymph node (Figure 1, A and B). Ethiodol contrast medium was noted in the superficial inguinal, hypogastric, and iliac divisions. Eventually, the contrast medium advanced into the left lumbar lymphatic vessels and crossed over to the right of midline, partially outlining the periaortic lymphatic vessels up to the level of the second to the third lumbar vertebra of the cisterna chyli. The contrast medium was contained within the thoracic duct at the middle of the twelfth thoracic vertebra. A fluoroscopically guided study showed the extravasation of Ethiodol from the thoracic duct at the level of the twelfth thoracic vertebra. A metal wire was placed over the site to mark the level of extravasation of the contrast medium (Figure 3, A and B). Initial and delayed 24-hour follow-up radiographs documented the swelling of both feet as well as the circumvention of residual Ethiodol contrast medium into the superficial and dermal lymphatic vessels of the left foot and leg (Figure 2, A and B). The images featured in this report best display the causes of the patient’s lymphedema tarda and the extravasation of Ethiodol as previously described.

In July 2005, treatment with pegylated interferon and ribavirin was discontinued. The following month, therapy with a low-fat medium-chain triglyceride and orlistat was begun. Although the frequency of paracentesis was not altered, the ascitic fluid triglyceride level decreased from a mean of 173 mg/dL to 75 mg/dL. The patient underwent the placement of a peritoneovenous shunt in October 2005. From October to February 2006, he required 3 paracentesis treatments. The mean (± SD) ascitic fluid triglyceride value on the day of each paracentesis treatment was 75 mg/dL (± 10.6 mg/dL), and the mean (± SD) serum albumin value was 3.7 g/dL (± 0.33 g/dL). Furthermore, the appearance of the ascitic fluid changed from milky to clear and straw-colored. Since February 2006, this patient has not required further paracentesis, and his lymphedema has resolved. Abdominal ultrasonography in March 2006 revealed no ascites, and his hepatitis C viral load was undetectable.


Chylous ascites is a rare finding that was shown in a study by Press and colleagues to occur with an incidence of approximately 1 in 20,000 admissions to a large university-based hospital over a 20-year period [4]. However, it is widely believed that the incidence of chylous ascites has increased because of more aggressive cardiothoracic and abdominal surgery as well as the longer survival of patients with cancer [5]. Chylous ascites can be caused by any of 3 mechanisms: obstruction of the major lymphatic channels at the base of the mesentery or the cisterna chyli, which causes leakage of chyle from dilated mesenteric lymphatic vessels; direct leakage of chyle through a lymphoperitoneal fistula created by abnormal or injured retroperitoneal lymphatic vessels; or the exudation of chyle through the retroperitoneal megalymphatic vessels without a visible fistula or obstruction of the thoracic duct [6].

Chylous ascites is caused by an abdominal malignacy or cirrhosis in more than two-thirds of all patients [1]. As many as half of those malignancies are lymphomas [1, 5]. Injury during abdominal aortic surgery, which is the most common cause of postoperative chylous ascites, results in 81% of all chylous complications [7]. Nevertheless, chylous ascites accounts for fewer than 1% of all complications after vascular surgery involving the abdominal aorta [8]. Warren shunts are an uncommon cause of chylous ascites [9], and chylous ascites rarely develops after liver transplantation [2, 10, 11]. We presumed that the development of chylous ascites after OLT in our patient (who did not exhibit ascites before his liver transplant) was caused by the disruption of lymphatic vessels near the porta hepatis or the retrohepatic area during the dissection and removal of the native liver.

Primary lymphedema, which results from aplasia or hypoplasia of the lymphatics, is thought to be a genetically determined disease, the expression of which varies by the patient’s age at onset [12]. There are several primary causes for lymphedema: Milroy disease, a rare disorder in which the patient demonstrates a lymphatic malformation at birth; lymphedema praecox, which has an onset at or near puberty; and lymphedema tarda (Meige disease). Lymphedema tarda is the rarest developmental abnormality of the lymphatic system and is not clinically evident until the patient is 35 years of age or older. The manifestation of lymphedema tarda usually follows a precipitating event such as trauma or an inflammatory reaction [12].

The time of onset of lymphedema may be associated with the relative number of functioning lymphatic vessels. It is generally thought that the fewer the lymphatic vessels, the earlier the onset of lymphedema. Patients with lymphedema often exhibit absent or incompetent lymphatic valves. The results of a lymphangiogram revealed lymphedema tarda in our patient. In our opinion, our patient’s lymphedema was clinically manifested only after a secondary insult (in his case, the development of chylous ascites that was likely caused by a leaking lymphatic vessel, located in the area of surgical dissection, that impeded lymph return).

Chylous ascites frequently causes painless abdominal distension [13]. Abdominal paracentesis is the most important diagnostic tool in evaluating and managing patients with ascites. In contrast to the straw-colored and transparent appearance of ascites caused by cirrhosis and portal hypertension, chylous ascites usually has a cloudy and turbid appearance. The triglyceride value in ascitic fluid (which is typically higher than 200 mg/dL, although some clinicians use a cutoff value of 110 mg/dL [14, 15]) is very important in identifying chylous ascites. Radiographic studies useful in the diagnosis and management of chylous ascites include computed tomography (which reveals pathologic intra-abdominal lymph nodes and masses) and lymphangiography and lymphoscintigraphy (which show abnormal retroperitoneal nodes, leakage from dilated lymphatic vessels, fistulization, and the patency of the thoracic duct) [16, 17]. Lymphangiography, which is the gold standard for identifying obstructions, may result in complications such as reactions to the contrast medium, transient lymphedema, tissue necrosis, or fat embolism [5, 16].

The management of chylous ascites remains controversial, but current treatments include repeated therapeutic paracentesis; a high-protein, low-fat, medium-chain–triglyceride diet; total parenteral nutrition (TPN); diuretics; the placement of a transjugular intrahepatic portosystemic shunt; peritoneovenous shunting; percutaneous coiling of the thoracic duct; or surgical ligation of the disrupted lymphatic channel [1, 18, 19]. The use of TPN in combination with octreotide has been reported to result in the rapid resolution of chylous ascites after liver transplantation [7]. It has been speculated that somatostatin improves chylous ascites by inhibiting lymph fluid excretion through specific receptors found in the normal intestinal wall of lymphatic vessels [7]. In a retrospective review of 156 patients with chylous ascites from various causes, 51 patients were successfully treated surgically (41% with the ligation of a leak, 39% with a peritoneovenous shunt, 10% with resection, and 10% with another surgical technique such as a peritoneal fluid filtration circuit) [5]. Of the 105 remaining patients who were treated conservatively, 67% were treated successfully. Forty-three percent of those individuals achieved success by dietary modification alone; a combination of diet, TPN, and paracentesis was successful in 26%; TPN alone produced resolution in 14%; and paracentesis alone was successful in 7% [5].

Our patient was initially treated with orlistat (which was recently reported to have benefitted a patient with chylous ascites [20]) and a high-protein, low-fat, medium-chain–triglyceride diet. When those measures were unsuccessful, he underwent the placement of a peritoneovenous shunt. Eventually, he experienced the resolution of both his chylous ascites and the edema caused by abnormal lymphatic drainage. Our case report should increase the awareness that congenital anomalies of the lymphatic system, when exacerbated by surgical procedures such as OLT, are often indicated by edema of the lower extremities.


  1. Cárdenas A, Chopra S. Chylous ascites. Am J Gastroenterol 2002; 98: 1896-1900
  2. Asfar S, Lowndes R, Wall WJ. Chylous ascites after liver transplantation. Transplantation 1994; 58: 368-369
  3. Segal J, Turner AF. Lymphedema tarda. JAMA 1976; 235: 1996-1997
  4. Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med 1982; 96: 358-364
  5. Aalami OO, Allen DB, Organ CH Jr. Chylous ascites: A collective review. Surgery 2000; 128: 761-778
  6. Turnage RH, Li BDL, McDonald JC. Abdominal wall, umbilicus, peritoneum, mesenteries, omentum, and retroperitoneum. In: Townsend CM, Beauchamp RD, eds. Sabiston Textbook of Surgery 17th ed. Philadelphia: WB Saunders, 2004, p 1171-1198
  7. Combe J, Buniet JM, Douge C, Bernard Y, Camelot G. Chylothorax and chylous ascites following surgery of an inflammatory aortic aneurysm. Case report with review of the literature. J Mal Vasc 1992; 17: 151-156
  8. Halloul Z, Meyer F, Burger T. Lippert H. Chylous ascites, a rare complication of aortic surgery. Vasa 1995; 24: 377-381
  9. Maywood BT, Goldstein L, Busuttil RW. Chylous ascites after a Warren shunt. Am J Surg 1978; 135: 700-702
  10. Senyuz OF, Senturk H, Tasci H, Kaya G, Ozbay G, Sariyar M. Chylous ascites after liver transplantation with mesentero-portal jump graft. J Hepatobiliary Pancreat Surg 2001; 8: 571-572
  11. Shapiro AM, Bain VG, Sigalet DL, Kneteman NM. Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total parenteral nutrition. Transplantation 1996; 61: 1410-1401
  12. Wyatt L, Pribaz J. Lymphedema. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology 3rd ed. New York: Churchill Livingstone; 2003, p 817-834
  13. Browse NL, Wilson NM, Russo F, al-Hassan H, Allen DR. Aetiology and treatment of chylous ascites. Br J Surg 1992; 79: 1145-1150
  14. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104-1109
  15. Jungst D, Gerbes AL, Martin R, Paumgartner G. Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology 1986; 6: 239-243
  16. Pui MH, Yueh TC. Lymphoscintigraphy in chyluria, chyloperitonum and chylothorax. J Nucl Med 1998; 39: 1292
  17. Collins JD, Disher AC, Shaver ML, Miller TQ. Imaging the hepatic lymphatics: experimental studies in swine. J Natl Med Assoc 1993 85: 185-191
  18. Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol 2002; 167: 449-457
  19. de Vries GJ, Ryan B, de Bievre M, Driessen A, Stockbrugger RW, Koek GH. Cirrhosis related chylous ascites successfully treated with TIPS. Eur J Gastroenterol Hepatol 2005; 17: 463-466
  20. Chen J, Lin RK, Hassanein T. Use of orlistat (xenical) to treat chylous ascites. J Clin Gastroenterol 2005; 39: 831-833

Volume : 4
Issue : 2
Pages : 567-570



1Department of Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California, 2Department of Medicine, School of Medicine, University of California at San Francisco, San Francisco, California, 3Department of Radiology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California, 1,4,5Department of Surgery, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California
Address reprint requests to: Sammy Saab, MD, MPH, Pfleger Liver Institute, 200 UCLA Medical Plaza, Suite 214, Box 957302, Los Angeles, CA 90095-7302
Phone: 00 310 206 67 05
Fax: 00 310 206 41 97


Figure 1, A and B. Anteroposterior fluoroscopic spot images capture the Ethiodol contrast medium as it advances within a single lymphatic vessel in the left thigh and inguinal region. A) Ethiodol contrast medium flowing within a dilated efferent lymphatic vessel over the medial left thigh and into a single superficial inguinal lymph node. B) The single lymphatic vessel in
Figure A divides into 2 afferent lymphatic vessels in the superficial lymph node; note the dilated afferent lymphatic vessels that fill over the region of the left ischium and acetabulum.

LYM, Lymphatic vessel; LN, lymph node; BI, bicuspid valves; F, femur; IS, left ischium; LT, lesser tuberosity of the femur; PU, pubic bone.


Figure 2, A and B. A) An anteroposterior fluoroscopic spot image of the left foot and ankle 24 hours after the injection of Ethiodol contrast medium into the lymphatic vessels over the dorsum of the left foot. Note the dense swelling of the ankle and foot. B) An anteroposterior fluoroscopic spot image of the lower left extremity 24 hours after the injection of Ethiodol contrast
medium into the lymphatic vessels over the dorsum of the left foot. This image displays the dermal and subcutaneous tissue backflow of the Ethiodol contrast medium into lymphatic vessels, which indicates circumvention and impedance to forward flow.

F, Fibula; T, tibia; LY, lymphatic vessels; L, left; X, dense swelling of the ankle and foot.


Figure 3, A and B. These figures are fluoroscopic images acquired as Ethiodol contrast medium extravasates from the region of the thoracic lymph duct over the twelfth thoracic vertebra. A) The patient was quietly breathing during this study. Bile duct tubing with a wire shows the dilation of the vessel and the extravasation of Ethiodol from the thoracic duct at the second lumbar vertebra. B) A fluoroscopic image captured during the Valsalva maneuver, which increased the patient’s abdominal pressure and caused the Ethiodol in Figure B to exit via the thoracic lymph duct.

BT, Bile duct tubing; W, wire; TD, thoracic duct; T12, twelfth thoracic vertebra; L2, second lumbar vertebra; A, aorta.


Copyright © Baskent University 2003. Printed in Turkey. All Rights Reserved.